trial

Oxytocin as Adjunctive Therapy for Schizophrenia

NCTId NCT01699997
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 32 (actual)
Sponsored by IRCCS Centro San Giovanni di Dio Fatebenefratelli
Primary completion 2015-04
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
32 (actual)
Study type
Interventional
Allocation
Randomized
Model
Crossover
Masking
Quadruple
Start
2014-01
Primary completion
2015-04
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
Oxytocin

Sponsors

IRCCS Centro San Giovanni di Dio FatebenefratelliLead Sponsor

Investigators

1
Giovanni de Girolamo, M.D.Principal Investigator

Sites

7 total
Urbino, ItalyBrescia, ItalyDesenzano, ItalyMilan, ItalyPadua, ItalyPisa, ItalyUdine, Italy

Linked catalysts

1
Oxytocin as Adjunctive Therapy for Schizophrenia — primary completion2015-04

Facts & assertions

4 sourced
Enrollment
32
Phase
PHASE2
Primary Completion Date
2015-04
Status
COMPLETED
relationships
The graph out of here
drug
Oxytocin
drug
lead_sponsor
IRCCS Centro San Giovanni di Dio Fatebenefratelli
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Giovanni de Girolamo, M.D.
person